Zanidatamab is generating momentum in early-stage HER2-positive breast cancer with NeoZanHER, a NeoZanHER phase 2 trial evaluating the next-generation dual-attack antibody zanidatamab in patients before surgery. The approach targets HER2 signaling through two binding modes, aiming to increase pathologic response in the preoperative setting. In parallel, Australian researchers reported a mechanistic vulnerability that may help explain how triple-negative breast cancer spreads systemically. The study, led through Adelaide University and the Olivia Newton-John Cancer Research Institute, describes a regulatory system tied to aggressive dissemination and suggests a route to repurpose an existing anti-cancer drug. Finally, UK-based work highlighted how a molecular switch, GPR52, can drive coordinated collective invasion in breast cancer models—adding another candidate biology axis for therapies aimed at metastatic behavior rather than tumor size alone.